Evoke Pharma Inc
NASDAQ:EVOK

Watchlist Manager
Evoke Pharma Inc Logo
Evoke Pharma Inc
NASDAQ:EVOK
Watchlist
Price: 24.7 USD 6.93% Market Closed
Market Cap: 21.1m USD

Operating Margin
Evoke Pharma Inc

-36%
Current
-147%
Average
5.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-36%
=
Operating Profit
-5.2m
/
Revenue
14.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Evoke Pharma Inc
NASDAQ:EVOK
21.1m USD
-36%
US
Eli Lilly and Co
NYSE:LLY
982.7B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
528.3B USD
27%
CH
Roche Holding AG
SIX:ROG
276B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
218.7B GBP
24%
CH
Novartis AG
SIX:NOVN
220B CHF
33%
US
Merck & Co Inc
NYSE:MRK
273.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
146.1B USD
29%
No Stocks Found

Evoke Pharma Inc
Glance View

Market Cap
21.1m USD
Industry
Pharmaceuticals

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

EVOK Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-36%
=
Operating Profit
-5.2m
/
Revenue
14.4m
What is the Operating Margin of Evoke Pharma Inc?

Based on Evoke Pharma Inc's most recent financial statements, the company has Operating Margin of -36%.

Back to Top